Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852348 | 0.95 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL852936 | 0.90 | TLR7 (0.78) | TLR7TLR8 | |
| SCHEMBL2847591 | 0.87 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL4215928 | 0.87 | TLR7 (0.83) | TLR7TLR8 | |
| SCHEMBL29378963 | 0.86 | TLR7 (0.78) | TLR7 | |
| SCHEMBL4214225 | 0.86 | TLR7 (0.78) | TLR7 | |
| SCHEMBL2850249 | 0.85 | TLR7 (1.00) | TLR7 | |
| SCHEMBL2850720 | 0.85 | TLR8 (0.72) | TLR7TLR8 | |
| SCHEMBL3700185 | 0.83 | TLR7 (0.73) | TLR7TLR8 | |
| SCHEMBL2845663 | 0.83 | TLR7 (0.78) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765939-B2 | Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers | ASTRAZENECA AB (SE) | 2014-07-01 | — | — | US | disclosed |
| US-20130045955-A1 | NOVEL COMPOUNDS | BENNETT NICHOLAS J (GB) | 2013-02-21 | — | — | US | disclosed |
| EP-2222648-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2013-01-09 | — | — | EP | disclosed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | TLR7 3271/4885TLR8 4435/4885 |
| US-20130045955-A1 | NOVEL COMPOUNDS | ABCG2, F12, CFTR | TLR7 2987/4885TLR8 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.